Prostate volumes derived from MRI and volume-adjusted serum prostate-specific antigen: Correlation with Gleason score of prostate cancer

American Journal of Roentgenology

Volumn 201, Issue 5, 2013, Pages 1041-1048

  Karademir, Ibrahim ^a   Shen, Dinggang ^b   Peng, Yahui ^a   Liao, Shu ^b   Jiang, Yulei ^a   Yousuf, Ambereen ^a   Karczmar, Gregory ^a   Sammet, Steffen ^a   Wang, Shiyang ^a   Medved, Milica ^a   Antic, Tatjana ^a   Eggener, Scott ^a   Oto, Aytekin ^a  

^a UNIVERSITY OF CHICAGO   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Gleason score; MRI; Prostate cancer

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; GLEASON SCORE; HUMAN; MAJOR CLINICAL STUDY; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SCANNER; PREDICTIVE VALUE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE VOLUME; PROSTATE WEIGHT; PROSTATECTOMY; REFERENCE VALUE; SENSITIVITY AND SPECIFICITY;

AGED; CONTRAST MEDIA; GADOLINIUM DTPA; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; NEOPLASM GRADING; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES; TUMOR BURDEN; TUMOR MARKERS, BIOLOGICAL;

EID: 84886504974     PISSN: 0361803X     EISSN: 15463141     Source Type: Journal    
DOI: 10.2214/AJR.13.10591     Document Type: Article

References (44)

1. D'Amico AV, Whittington R, Malkowicz SB, et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 1998; 280:969-974
2. Partin AW, Mangold LA, Lamm DM, Walsh PC, Epstein JI, Pearson JD. Contemporary update of prostate cancer staging nomograms (Partin Tables) for the new millennium. Urology 2001; 58: 843-848
3. D'Amico AV, Moul J, Carroll PR, Sun L, Lubeck D, Chen MH. Cancer-specific mortality after surgery or radiation for patients with clinically localized prostate cancer managed during the prostate-specific antigen era. J Clin Oncol 2003; 21:2163-2172
4. Stephenson AJ, Scardino PT, Eastham JA, et al. Preoperative nomogram predicting the 10-year probability of prostate cancer recurrence after radical prostatectomy. J Natl Cancer Inst 2006; 98:715-717
5. Bill-Axelson A, Holmberg L, Ruutu M, et al. Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med 2005; 352:1977-1984
6. Daskivich TJ, Chamie K, Kwan L, et al. Overtreatment of men with low-risk prostate cancer and significant comorbidity. Cancer 2011; 117:2058-2066
7. Welch HG, Albertsen PC. Prostate cancer diagnosis and treatment after the introduction of prostate-specific antigen screening: 1986-2005. J Natl Cancer Inst 2009; 101:1325-1329
8. McNeal JE. Regional morphology and pathology of the prostate. Am J Clin Pathol 1968; 49:347-357
9. Augustin H, Erbersdobler A, Hammerer PG, Graefen M, Huland H. Prostate cancers in the transition zone. Part 2. Clinical aspects. BJU Int 2004; 94:1226-1229
10. Stamey TA, Dietrick DD, Issa MM. Large, organ confined, impalpable transition zone prostate cancer: association with metastatic levels of prostate specific antigen. J Urol 1993; 149:510-515
11. Noguchi M, Stamey TA, Neal JE, Yemoto CE. An analysis of 148 consecutive transition zone cancers: clinical and histological characteristics. J Urol 2000; 163:1751-1755
12. Augustin H, Erbersdobler A, Graefen M, et al. Biochemical recurrence following radical prostatectomy: a comparison between prostate cancers located in different anatomical zones. Prostate 2003; 55:48-54
13. Lee F, Siders DB, Torp-Pedersen ST, Kirscht JL, McHugh TA, Mitchell AE. Prostate cancer: transrectal ultrasound and pathology comparison: a preliminary study of outer gland (peripheral and central zones) and inner gland (transition zone) cancer. Cancer 1991; 67(suppl):1132-1142
14. Ishida J, Sugimura K, Okizuka H, et al. Benign prostatic hyperplasia: value of MR imaging for determining histologic type. Radiology 1994; 190:329-331
15. Kahn T, Bürrig K, Schmitz-Dräger B, Lewin JS, Fürst G, Mödder U. Prostatic carcinoma and benign prostatic hyperplasia: MR imaging with histopathologic correlation. Radiology 1989; 173:847-851
16. Schiebler ML, Tomaszewski JE, Bezzi M, et al. Prostatic carcinoma and benign prostatic hyperplasia: correlation of high-resolution MR and histopathologic findings. Radiology 1989; 172:131-137
17. Hricak H, Dooms GC, McNeal JE, et al. MR imaging of the prostate gland: normal anatomy. AJR 1987; 148:51-58
18. Sommer FG, McNeal JE, Carrol CL. MR depiction of zonal anatomy of the prostate at 1.5 T. J Comput Assist Tomogr 1986; 10:983-989
19. Oto A, Kayhan A, Jiang Y, et al. Prostate cancer: differentiation of central gland cancer from benign prostatic hyperplasia by using diffusionweighted and dynamic contrast-enhanced MR imaging. Radiology 2010; 257:715-723
20. Lee JS, Chung BH. Transrectal ultrasound versus magnetic resonance imaging in the estimation of prostate volume as compared with radical prostatectomy specimens. Urol Int 2007; 78:323-327
21. Jeong CW, Park HK, Hong SK, Byun SS, Lee HJ, Lee SE. Comparison of prostate volume measured by transrectal ultrasonography and MRI with the actual prostate volume measured after radical prostatectomy. Urol Int 2008; 81:179-185
22. Milosevic M, Voruganti S, Blend R, et al. Magnetic resonance imaging (MRI) for localization of the prostatic apex: comparison to computed tomography (CT) and urethrography. Radiother Oncol 1998; 47:277-284
23. Choi YJ, Kim JK, Kim HJ, Cho KS. Interobserver variability of transrectal ultrasound for prostate volume measurement according to volume and observer experience. AJR 2009; 192:444-449
24. Jia G, Baudendistel KT, von Tengg-Kobligk H, et al. Assessing prostate volume by magnetic resonance imaging: a comparison of different measurement approaches for organ volume analysis. Invest Radiol 2005; 40:243-248
25. Bulman JC, Toth R, Patel AD, et al. Automated computer-derived prostate volumes from MR imaging data: comparison with radiologist-derived MR imaging and pathologic specimen volumes. Radiology 2012; 262:144-151
26. Liao S, Gao Y, Shen D. Sparse patch based prostate segmentation in CT images. Med Image Comput Comput Assist Interv 2012; 15:385-392
27. Rodriguez E Jr, Skarecky D, Narula N, Ahlering TE. Prostate volume estimation using the ellipsoid formula consistently underestimates actual gland size. J Urol 2008; 179:501-503
28. Varma M, Morgan JM. The weight of the prostate gland is an excellent surrogate for gland volume. Histopathology 2010; 57:55-58
29. Ohlsén H, Ekman P, Ringertz H. Assessment of prostatic size with computed tomography: methodologic aspects. Acta Radiol Diagn (Stockh) 1982; 23(3A):219-223
30. Metz CE, Pan X. "Proper" binormal ROC curves: theory and maximum-likelihood estimation. J Math Psychol 1999; 43:1-33
31. Kaplan SA, Te AE, Pressler LB, Olsson CA. Transition zone index as a method of assessing benign prostatic hyperplasia: correlation with symptoms, urine flow and detrusor pressure. J Urol 1995; 154:1764-1769
32. Kalish J, Cooner WH, Graham SD Jr. Serum PSA adjusted for volume of transition zone (PSAT) is more accurate than PSA adjusted for total gland volume (PSAD) in detecting adenocarcinoma of the prostate. Urology 1994; 43:601-606
33. Tewari A, Shinohara K, Narayan P. Transition zone volume and transition zone ratio: predictor of uroflow response to finasteride therapy in benign prostatic hyperplasia patients. Urology 1995; 45:258-264
34. Djavan B, Zlotta AR, Byttebier G, et al. Prostate specific antigen density of the transition zone for early detection of prostate cancer. J Urol 1998; 160:411-418
35. Djavan B, Remzi M, Zlotta AR, et al. Complexed prostate-specific antigen, complexed prostate-specific antigen density of total and transition zone, complexed/total prostate-specific antigen ratio, free-to-total prostate-specific antigen ratio, density of total and transition zone prostate-specific antigen: results of the prospective multicenter European trial. Urology 2002; 60(suppl 1):4-9
36. Kang SH, Bae JH, Park HS, et al. Prostate-specific antigen adjusted for the transition zone volume as a second screening test: a prospective study of 248 cases. Int J Urol 2006; 13:910-914
37. Zlotta AR, Djavan B, Petein M, Susani M, Marberger M, Schulman CC. Prostate specific antigen density of the transition zone for predicting pathological stage of localized prostate cancer in patients with serum prostate specific antigen less than 10 ng/ml. J Urol 1998; 160:2089-2095
38. Ohi M, Ito K, Suzuki K, Yamamoto T, Yamanaka H. Diagnostic significance of PSA density adjusted by transition zone volume in males with PSA levels between 2 and 4 ng/ml. Eur Urol 2004; 45:92-96
39. Ohigashi T, Kanao K, Mizuno R, Kikuchi E, Nakashima J, Oya M. Predicting the probability of significant prostate cancer in Japanese men with serum prostate-specific antigen less than 10 ng/mL: development of a novel pre-biopsy nomogram. Int J Urol 2010; 17:274-280
40. Tanaka N, Fujimoto K, Chihara Y, et al. Prostatic volume and volume-adjusted prostate-specific antigen as predictive parameters for prostate cancer patients with intermediate PSA levels. Prostate Cancer Prostatic Dis 2007; 10:274-278
41. Catalona WJ, Richie JP, Ahmann FR, et al. Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: result of a multicenter trial of 6,630 men. J Urol 1994; 151:1283-1290
42. Lin K, Croswell JM, Koenig H, Lam C, Maltz A. Prostate-specific antigen-based screening for prostate cancer: an evidence update for the U.S. Preventive Services Task Force - evidence synthesis, no. 90. AHRQ Publication No. 12-05160-EF-1. Rockville, MD: Agency for Healthcare Research and Quality, 2011
43. Benson MC, Whang IS, Olsson CA, McMahon DJ, Cooner WH. The use of prostate specific antigen density to enhance the predictive value of intermediate levels of serum prostate specific antigen. J Urol 1992; 147:817-821
44. McNeal JE. The prostate gland: morphology and pathobiology. Monogr Urol 1983; 4:5-13